Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploring the Resistance Mechanisms of Distal D835V Mutation in FLT3 to Inhibitors.

Oxidative medicine and cellular longevity - 1 Jan 2022

Wang Zhiwei, Hu Baichun, An Yu, Wang Jian

Abstract excerpt

Objective: FMS-like tyrosine kinase 3 (FLT3) is an attractive therapeutic target in acute myeloid leukemia. Unfortunately, secondary FLT3 mutations that developed resistance to inhibitors have become a severe problem. Specifically, ASP-835 (D835F/H/V/Y) mutant within the activation loop of FLT3 is the most commonly encountered drug-resistant and observed secondary FLT3 mutations. In this study, we carried out a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Sorafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 35387260
DOI: 10.1155/2022/3720026
PMCID: PMC8979743

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploring the Resistance Mechanisms of Distal D835V Mutation in FLT3 to Inhibitors.PMID 35387260Read ↗

The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach.Semantic proximity Read ↗

Deciphering the mechanism of HM43239 inhibiting the mutant F691L resistant to gilteritinib in FMS-like tyrosine kinase 3.Semantic proximity Read ↗

Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy.Semantic proximity Read ↗

FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors.Semantic proximity Read ↗

Deciphering the molecular mechanism of FLT3 resistance mutations.Semantic proximity Read ↗

Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations.Semantic proximity Read ↗

Molecular Dynamics Studies on D835N Mutation in FLT3—Its Impact on FLT3 Protein StructureSemantic proximity Read ↗

In silico and in vitro study of FLT3 inhibitors and their application in acute myeloid leukemia.Semantic proximity Read ↗

Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.Semantic proximity Read ↗

Landscape of FLT3 Variations Associated with Structural and Functional Impact on Acute Myeloid Leukemia: A Computational Study.Semantic proximity Read ↗

Elucidating the potential effects of point mutations on FGFR3 inhibitor resistance via combined molecular dynamics simulation and community network analysis.Semantic proximity Read ↗

The molecular mechanism behind resistance of the kinase FLT3 to the inhibitor quizartinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.